Apollo Hospitals Enterprise Limited has delivered a robust financial performance for the third quarter of the 2026 financial year, underscoring its dominance in the Indian healthcare landscape. The leading hospital chain reported a 35% year-on-year surge in consolidated net profit, reaching 502 crore. Total revenue for the quarter rose to 6,477 crore, marking a 17% increase compared to the previous year. This growth was fueled by strong demand across its core verticals, particularly in specialized medical services and the digital health ecosystem. The Board of Directors has declared an interim dividend of 10 per share for the financial year 2026. This represents 200% of the face value of 5 per share. Shareholders on record as of February 16, 2026, will be eligible for this payout, with the distribution scheduled for completion by the end of the month. Healthcare services, the company’s primary revenue driver, maintained high operational efficiency. Average revenue per occupied bed (ARPOB) saw a healthy 9% improvement, reflecting a shift toward high-acuity treatments in oncology, neurology, and cardiology. Overall bed occupancy across the network remained steady at approximately 69% to 70%. The pharmacy and digital health segment, operated through Apollo HealthCo, continued its trajectory toward breakeven. The Apollo 24/7 platform expanded its reach to 44 million users, contributing to a Gross Merchandise Value (GMV) of 723 crore during the period. The offline pharmacy network also expanded, surpassing 6,900 stores nationwide. Looking ahead, Apollo Hospitals is executing an aggressive capacity expansion plan. The company aims to add 1,600 new beds over the next year and a half, part of a broader strategy to increase its total capacity from 10,200 beds to over 14,000 beds. This expansion is expected to contribute an additional 5% to revenue growth as new facilities ramp up operations. Market sentiment remains positive as the healthcare sector in India continues to benefit from increased government spending and a resurgence in medical tourism. Apollo’s strategic focus on integrating AI-driven diagnostics and remote robotic surgeries positions it to capture a significant share of this evolving market. The stock continues to be a key constituent of the Nifty 50, with a market capitalization exceeding 1,03,000 crore. Investors remain focused on the company’s ability to balance its heavy capital expenditure on new beds with the improving profitability of its digital and diagnostic arms.